DiaSorin, a biotechnology company, has received all the marketing approvals for hepatitis, retroviral and syphilis assays on its Liaison XL platform for the Chinese market.
DiaSorin is now entering the hepatitis B, hepatitis C and retroviruses’ segments in China with its complete panel for the pre-surgical screening testing.
DiaSorin is putting all its efforts to expand its footprint targeting the diagnostic lab activity of hepatitis and retroviruses testing and aims to become a player in this important segment, further enhancing and consolidating its positioning in the Chinese market.
DiaSorin commercial operations senior corporate vice president Chen Even said the Chinese market is growing rapidly and the demand for testing of infectious diseases is particularly strong.
"With the approval of these new tests we reach an important milestone and strengthen our presence in a market that will increasingly contribute more to the growth of Group in the near future," Even added.
The new tests include the complete panel of hepatitis B, hepatitis C, HIV and Treponema assays. These include HBsAg Quant, Anti-HBs II, Anti-HBc, Anti-HBe, HBeAg, HCV Ab, HIV Ab/Ag and Treponema.
Anti-HBs II is a test for the quantitative determination of antibody to hepatitis B surface antigen (anti-HBs). Anti-HBc is a test for the qualitative determination of total antibodies to hepatitis B core antigen (anti-HBc)
Anti-HBe is a test for the qualitative determination of total antibodies to hepatitis B ‘e’ antigen (anti-HBe). HBeAg is a test for the quantitative determination of ‘e’ antigen of hepatitis B virus (HBeAg).
HCV Ab for hepatitis C screening and diagnosis – qualitative determination of specific antibodies to hepatitis C virus (anti-HCV). HIV Ab/Ag for HIV screening and diagnosis – combined qualitative determination of p24 antigen and specific antibodies to human immunodeficiency viruses.
Treponema is for diagnosis of syphilis infection – qualitative determination of specific total antibodies to Treponema pallidum.